The Senior HR Business Partner (Sr. HRBP) serves as a strategic partner to senior leaders, with a primary focus on supporting the Research & Development (R&D) organization during a pivotal pre-commercial stage. This role is instrumental in shaping organizational design, building leadership capability, and driving a high-performance, innovation-driven culture. The Sr. HRBP will bring a forward-looking, business-oriented perspective to talent strategy, enabling the organization to scale effectively while advancing critical pipeline programs toward commercialization.
Essential Functions:
Requirements:
Bachelor’s degree with 8+ years of progressive HR experience, ideally within biotech, pharmaceutical, or life sciences; HR certification a plus. Other combinations of education and/or experience may be considered.
Reports to: Director, HR Business Partner
Location: San Carlos, CA
Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy): Hybrid (minimum of 2-3 days per week onsite)
Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $170,000 – $200,000 (SF Bay Area).
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.

Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, our 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
We are re-engineering the way highly complex vaccines are made. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
In addition to our PCV franchise, our pipeline includes early-stage programs targeting Group A Strep, periodontitis and Shigella. At Vaxcyte, we are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.